Fujifilm invests $2B on cell culture manufacturing

By The Science Advisory Board staff writers

Fujifilm plans to invest more than $2 billion to build a large-scale cell culture manufacturing site for biopharmaceuticals in the U.S.

The company's subsidiary, Fujifilm Diosynth Biotechnologies, will operate the new facility, which will provide drug substance manufacturing, fill-finish and assembly, packaging, and labeling services, according to the firm. The facility will house eight 20,000-L bioreactors with the potential to expand and add 24 more bioreactors of the same size.

The new compound will be located near an existing U.S. Fujifilm site, and is expected to begin operations in the spring of 2025, Fujifilm said.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: